Clinical trials: Refractory
Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
This is a phase 3, randomized, 2-arm, open-label, international trial evaluating alisertib compared with single-agent treatment, as selected by the investigator from the offered options of pralatrexate or gemcitabine or…
- Trial name
- NCT01482962
- Testing
- Alisertib, Pralatrexate, Gemcitabine
- Where
- 151 sites in United States, Australia and 29 more
- Volunteers
- 271 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Venetoclax Combined With Azacitidine Plus Homoharringtonine, Venetoclax Combined With Azacitidine
VAH Versus VA for Salvage Therapy of R/R-AML
This is a prospective, multi-center, phase 3 randomized controlled clinical study comparing VAH and VA regimens for the salvage treatment of the patients with relapsed/refractory AML.
- Trial name
- NCT05457361
- Testing
- VEN combined with azacitidine plus homoharringtonine, VEN combined with azacitidine
- Where
- China
- Volunteers
- 162 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Glioma, Sarcoma
A Phase I Study of SU101 in Pediatric Patients With Refractory Malignancy
A dose escalation scale consisting of 5 dosage levels is being used to determine the maximum tolerated dose (MTD) of SU101. A minimum of 3 and a maximum of 6 patients will be enrolled at each dose level.
- Trial name
- NCT00001573
- Testing
- SU101
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Myeloma
Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple Myeloma
This is a 2 part study: Part 1 (dose escalation) and Part 2 (dose expansion). The goal of Part 1 of this clinical research study is to find the highest tolerable dose of DS-3032b that can be given to patients with multiple…
- Trial name
- NCT02579824
- Testing
- DS-3032b
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma
- Trial name
- NCT00109824
- Testing
- decitabine, valproic acid, pharmacological study
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma and Plasma Cell Neoplasm
Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma
RATIONALE: Biological therapies, such as anti-thymocyte globulin, may stimulate the immune system in different ways and stop cancer cells from growing.
- Trial name
- NCT00635024
- Testing
- anti-thymocyte globulin, melphalan
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Mayo Clinic
Lymphoma, Mantle-Cell
A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma
The purpose of this study is to investigate and characterize the association of lenalidomide with tumor flare reaction and high tumor burden in participants with relapsed or refractory mantle cell lymphoma.
- Trial name
- NCT03647124
- Testing
- Lenalidomide
- Where
- 79 sites in Austria, France and 5 more
- Volunteers
- 105 people
- Sponsor
- Celgene
Acute Lymphoid Leukemia
Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy
To assess the efficacy (in terms of response rate and duration) of the infusion of ARI-0001 cells (Adult differentiated autologous T-cells from peripheral blood, expanded and transducted with a lentivirus to express a chimeric…
- Trial name
- CART19-BE-02 (NCT04778579)
- Testing
- ARI-0001 cells
- Where
- 9 sites in Spain
- Volunteers
- 50 people
- Sponsor
- Sara V. Latorre
Genital Neoplasms, Female
Intra-tumor Injection of Oncolytic Viruses H101 Combined With or Without Radiotherapy in Refractory/Recurrent Gynecological Malignancies
The purpose of this clinical trial is to evaluate the effectiveness and safety of oncolytic viruses H101 intra-tumor injection combined with or without radiotherapy in refractory or recurrent gynecological malignancies.
- Trial name
- NCT05051696
- Testing
- H101
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Liu Zi
Anemia
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q
The purpose of this study is to investigate whether lenalidomide would reduce the number of red blood cell transfusions (RBC) needed in anemic (RBC transfusion-dependent) participants with low or intermediate-1 risk MDS without a…
- Trial name
- MDS-005 (NCT01029262)
- Testing
- Lenalidomide
- Where
- 99 sites in United States, Australia and 14 more
- Volunteers
- 239 people
- Sponsor
- Celgene
Epilepsy
A Study for Evaluating the Efficacy and Safety of Zonisamide and Lamotrigine (Lamictal) for Subjects With Refractory Simple Partial, Complex Partial or Partial With Secondary Generalized Seizures
The purpose of this study is to evaluate the efficacy and safety of zonisamide for anti-epilepsy drugs (AEDs) treated subjects with refractory simple partial, complex partial or partial with secondary generalized seizures.
- Trial name
- NCT00292461
- Testing
- Zonisamide, Lamotrigine
- Where
- 8 sites in China
- Volunteers
- 64 people
- Sponsor
- Eisai Inc.
Leukemia, Aplastic Anemia
Methadone as an Alternative Treatment for Children Underdoing HSCT
Mucositis is a normal side effect of stem cell transplant which happens as a result of chemotherapy being given prior to a new donor cell infusion (bone marrow transplant).
- Conditions
- Leukemia, Aplastic Anemia, Bone Marrow Failure Syndromes, SCID
- Trial name
- MATCH (NCT06940570)
- Testing
- PCA plus methadone (Experimental), PCA Alone (SOC)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Texas Southwestern Medical Center
Chronic Pelvic Pain Syndrome
Combined Sono-electro-magnetic Therapy for Treatment of Refractory Chronic Pelvic Pain Syndrome
Treatment of chronic pelvic pain syndrome (CPPS) is challenging for patients and physicians once conventional therapies fail. We hypothesize that combined sono-electro-magnetic therapy can improve refractory CPPS in men.
- Trial name
- NCT00688506
- Testing
- combined sono-electro-magnetic therapy (Sonodyn Medico Star)
- Where
- Switzerland
- Volunteers
- 60 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Chronic Myeloproliferative Disorders, Leukemia
Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill metastatic cancer cells. Interferon alfa may interfere with the growth of the cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00002504
- Testing
- aldesleukin, recombinant interferon alfa
- Where
- 5 sites in United States
- Sponsor
- Hoag Memorial Hospital Presbyterian
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma
The purpose of this study is to evaluate the safety and tolerability of INCB053914 in combination with INCB050465 in relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
- Trial name
- NCT03688152
- Testing
- INCB053914, INCB050465
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Incyte Corporation
Osteosarcoma, Osteosarcoma, Recurrent, Refractory
68Ga-B7-H3 Nanobody ImmunoPET in Osteosarcoma
This study aims to evaluate the safety, feasibility, and imaging performance of a novel 68Ga-labeled B7-H3 nanobody for immunoPET imaging in patients with osteosarcoma.
- Trial name
- NCT07774533
- Testing
- 68Ga-B7-H3 Nanobody PET/CT
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Peking University First Hospital
Epilepsy and Focal Cortical Dysplasia II
A Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II)
This is a prospective, randomized, double-blind, placebo-controlled cross over study designed to evaluate the efficacy and safety of everolimus (trough 5-15 ng/mL) given as adjunctive therapy in patients with focal cortical…
- Trial name
- NCT03198949
- Testing
- Afinitor (everolimus)
- Where
- South Korea
- Volunteers
- 23 people
- Sponsor
- Yonsei University
Non Small Cell Lung Cancer
Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the safety and time to progression of HLA-A*2402 restricted epitope peptides URLC10, TTK and KOC1 emulsified with Montanide ISA 51.
- Trial name
- NCT00674258
- Testing
- URLC10, TTK and KOC1
- Where
- Japan
- Volunteers
- 14 people
- Sponsor
- Tokyo University
HER2 Positive Breast Cancer
A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer
Evaluating the Efficacy of Lapatinib in Combination With Chemotherapy in Patients With Trastuzumab-refractory Metastatic HER2-positive Breast Cancer.
- Trial name
- NCT02362958
- Testing
- lapatinib and capecitabine or vinorelbine
- Where
- China
- Volunteers
- 159 people
- Sponsor
- Sun Yat-sen University
Leukemia, Lymphoma
Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11)
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have newly…
- Trial name
- NCT00005626
- Testing
- Irinotecan
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute